research Guidelines for the Management of Tinea Capitis in Children
Systemic treatment is necessary for tinea capitis in children, with griseofulvin preferred for Microsporum infections.
Search
for
Sort by
Research
990-1000 / 1000+ results
research Cat Contact as A Risk Factor for Tinea Capitis Infection
Touching cats can increase the risk of getting a fungal scalp infection, especially in boys and kids over 5.
research Congenital Triangular Alopecia: A Case of Effective Response with 5% Topical Minoxidil in a Male Adolescent
5% topical minoxidil effectively treated a boy's congenital triangular alopecia without side effects.
research Topical and intralesional therapies for alopecia areata
No treatments fully cure or prevent alopecia areata; some help but have side effects or need more research.
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
research The therapeutic use of topical contact sensitizers in benign dermatoses
Topical contact sensitizers can treat certain skin conditions but are rarely used in the U.K.
research Successful treatment of alopecia areata‐associated trachyonychia with baricitinib
Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.
research Intralesional steroids for alopecia areata
Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.